Cancer Family
Malignant Neoplasm
CI-CAN-00000025CAExplore in graph →
20,116 active trials259 approved drugs3,741 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000025CAExplore in graph →
Clinical trials
90,685 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (11,163)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07790419 | A Prospective, Single-Arm, Open-Label Clinical Study of the Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Targeted Therapy and a PD-1 Inhibitor in Patients With Postoperative Hepatocellular Carcinoma and Microvascular Invasion | not yet recruiting | Phase 4 | 40 | Zhai WenlongOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07790601 | Swabs in Screening for HPV (SWISH)(SWISH) | not yet recruiting | N/A | 700 | Kirby InstituteOTHER_GOV | 1 | Aug 27, 2026 |
| clinicaltrials |
| NCT07790939 | 89Zr-DFO-Mirvetuximab PET/CT Imaging for Companion Diagnosis and Response Evaluation in Ovarian Cancer | not yet recruiting | Early Phase 1 | 20 | Peking University Cancer Hospital & InstituteOTHER | 0 | Aug 27, 2026 | clinicaltrials |
| NCT07791264 | FPS-ZM1 With or Without Dexamethasone for Controlling Post Operative Cerebral Edema in Patients With Glioblastoma | not yet recruiting | Phase 1 | 24 | City of Hope Medical CenterOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07791368 | Developing and Testing the Efficacy of AI-Chatbot-Based | not yet recruiting | N/A | 68 | National Taiwan University HospitalOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT03222674 | Multi-CAR T Cell Therapy for Acute Myeloid Leukemia | not yet recruiting | Phase 1 / Phase 2 | 10 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT03356782 | Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas | not yet recruiting | Phase 1 / Phase 2 | 20 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT03356808 | Antigen-specific T Cells Against Lung Cancer | not yet recruiting | Phase 1 / Phase 2 | 20 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT03614650 | Immunotherapy Treating GI Cancer | not yet recruiting | Phase 1 / Phase 2 | 100 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT04016129 | CAR-T Immunotherapy Targeting CD19- ALL | not yet recruiting | Phase 1 / Phase 2 | 100 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT04033302 | Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies | not yet recruiting | Phase 1 / Phase 2 | 30 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT04429438 | Multi-CAR-T Cells Targeting B Cell Lymphomas | not yet recruiting | Phase 1 / Phase 2 | 11 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT04430595 | Multi-4SCAR-T Therapy Targeting Breast Cancer | not yet recruiting | Phase 1 / Phase 2 | 100 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT04433221 | Combination Immunotherapy Targeting Sarcomas | not yet recruiting | Phase 1 / Phase 2 | 20 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT05995028 | Universal 4SCAR7U Targeting CD7-positive Malignancies | not yet recruiting | Phase 1 | 30 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT06006741 | Universal CAR-T Cells Targeting Multiple Myeloma | not yet recruiting | Phase 1 | 20 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT06656936 | The PharmFIT Study(PharmFIT) | not yet recruiting | N/A | 1,500 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07054944 | Tumor-Lymph Node Mapping(T-LyM) | not yet recruiting | — | 10 | University of RochesterOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07169617 | Testing the SurVaxM Vaccine for Lung Cancer Prevention | not yet recruiting | Phase 2 | 80 | National Cancer Institute (NCI)NIH | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07254650 | Combination Versus Alone Liposomal Bupivacaine Blocks in Minimally Invasive Thoracic Surgery-1(CALMS-1) | not yet recruiting | N/A | 300 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07341126 | Use of a Novel Camera to Check the Bowel After Polyp or Tumour Removal(R-ALERT) | not yet recruiting | — | 30 | University of EdinburghOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07349641 | A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer | not yet recruiting | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07494994 | SURGIMEDIA: Utilization of Multimedia for Enhanced Surgical Consent(SURGIMEDIA) | not yet recruiting | N/A | 60 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07551778 | Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 42 | BOE Technology Group Co., Ltd.INDUSTRY | 0 | Aug 26, 2026 | clinicaltrials |
| NCT07561645 | A Trial for the Treatment of Advanced Large-Cell Neuroendocrine Cancer of the Lung(ALPINE 2) | not yet recruiting | Phase 2 | 75 | Technische Universität DresdenOTHER | 0 | Aug 26, 2026 | clinicaltrials |
| NCT07648459 | CM336-SOC for Dynamically High-Risk Multiple Myeloma Study(CAREMM-013) | not yet recruiting | Phase 2 | 46 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Aug 26, 2026 | clinicaltrials |
| NCT07698990 | Segmentectomy Versus Lobectomy for Deep Solid-Dominant Early-Stage NSCLC(SOLID) | not yet recruiting | N/A | 1,200 | Shanghai Chest HospitalOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07720089 | Developing Pilot Postoperative Guidelines for Improved Functional Outcomes After High-Risk Cancer Surgery | not yet recruiting | N/A | 66 | University of Alabama at BirminghamOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07720726 | Impact of Dysport on PMFF Donor Scar | not yet recruiting | Phase 4 | 50 | Vanderbilt University Medical CenterOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07739186 | A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06) | not yet recruiting | Phase 2 / Phase 3 | 120 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07744243 | A Study of SI-B036 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors | not yet recruiting | Phase 1 | 30 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07754799 | A Randomized Trial of Venetoclax-Based Induction Intensity in Newly Diagnosed Acute Myeloid Leukemia | not yet recruiting | Phase 2 | 320 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Aug 26, 2026 | clinicaltrials |
| NCT07778602 | Safety and Feasibility of First-line Avutometinib and Defactinib in Patients With Newly Diagnosed High-grade Gliomas | not yet recruiting | Early Phase 1 | 22 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 2 | Aug 26, 2026 | clinicaltrials |
| NCT07781449 | Topical JAK-Inhibition of Early-Stage CTCL | not yet recruiting | Phase 2 | 15 | Aarhus University HospitalOTHER | 0 | Aug 26, 2026 | clinicaltrials |
| NCT07782840 | QL1706 Plus Neoadjuvant Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer With a Poor Response to Neoadjuvant Chemotherapy | not yet recruiting | Phase 2 | 40 | Hebei Medical University Fourth HospitalOTHER | 0 | Aug 26, 2026 | clinicaltrials |
| NCT07786376 | AI in Histipathological Diagnosis of Bcc(AI\bcc) | not yet recruiting | — | 50 | Al-Azhar UniversityOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07786428 | Tailored Neoadjuvant Chemoimmunotherapy for Stage I TNBC(DETENTE-1) | not yet recruiting | Phase 2 | 60 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07786909 | ERICA-02 Study : Impact of Physical Exercise on the Tumor Immune Microenvironment in Patients Treated With Neoadjuvant Chemoimmunotherapy for Non-small Cell Lung Cancer(ERICA-02) | not yet recruiting | N/A | 40 | Centre Leon BerardOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07787156 | Reach and Engagement of GENetic Education, Risk Assessment, and TEsting Feasibility Trial(REGENERATE) | not yet recruiting | N/A | 80 | Brigham and Women's HospitalOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07787338 | SHR-A1811 Monotherapy or Sequential THPy as Neoadjuvant Therapy for Stage II-III HER2-Positive Breast Cancer | not yet recruiting | Phase 2 | 80 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07788001 | A Non-inferiority Study of Indocyanine Green-guided Sentinel Lymph Node Mapping Versus Conventional Lymph Node Dissection in Esophageal Cancer(SIGN) | not yet recruiting | Phase 3 | 200 | Fujian Medical University Union HospitalOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07788222 | Sacituzumab Govitecan and Q901 in Advanced TNBC | not yet recruiting | Phase 2 | 48 | Yonsei UniversityOTHER | 0 | Aug 26, 2026 | clinicaltrials |
| NCT07788430 | Impact of Pesticide Exposure on Survival and Tumor Aggressiveness in Patients With Glioblastoma: A Prospective Clinical Study(EXPOGLIO) | not yet recruiting | N/A | 120 | Institut Claudius RegaudOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07788664 | Local and Systemic Immune Modulation by Rilvegostomig (AZD2936) in the Treatment of Advanced Gastric Cancer (RILVE Project)(RILVE) | not yet recruiting | Phase 2 | 50 | Vall d'Hebron Institute of OncologyOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT06024772 | Multiparametric Ultrasound for the Diagnosis of Clinically Significant Prostate Cancer | not yet recruiting | Phase 3 | 300 | Thomas Jefferson UniversityOTHER | 2 | Aug 25, 2026 | clinicaltrials |
| NCT07053020 | A Phase 1 Open-Label, Dose-Ranging Safety and Pharmacokinetics Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML) | not yet recruiting | Phase 1 / Phase 2 | 58 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07508995 | A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL) | not yet recruiting | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07771400 | Molecular Ovarian Cancer Assessment in LatiNoAmerican PAtients(MOANA) | not yet recruiting | — | 320 | Latin American Cooperative Oncology GroupOTHER | 4 | Aug 25, 2026 | clinicaltrials |
| NCT07780578 | The Study Of Andamertinib Plus Anlotinib In Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 | 34 | Fudan UniversityOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07780968 | Zanidatamab Outcomes and Lived Experiences in Advanced HER2+ GEA(ZOLA) | not yet recruiting | — | 300 | Jazz PharmaceuticalsINDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 27, 2026source: clinicaltrials